IDL Diagnostics AB (publ) (IDLDX.ST) Research

Specializing in in vitro diagnostics (IVD), IDL Diagnostics AB (publ) develops and markets diagnostic tests aimed at detecting cancer and bacterial infections within the Swedish market. Its product portfolio includes UBC Rapid, a point-of-care solution for both diagnosing and tracking bladder cancer; AroCell TK 210 ELISA, utilized as a biomarker for identifying tumor cells; and TUBEX TF, an in vitro diagnostic tool for pinpointing acute typhoid fever. Formerly operating as AroCell AB (publ), the company is scheduled to adopt the name IDL Diagnostics AB (publ) in May 2025. Established in 2000, its operations are headquartered in Stockholm, Sweden.

Market snapshot

Symbol
IDLDX.ST
Price
$0.45
Day change
+5.88%
Market cap
$103.7M
P/E ratio
41.67x
52-week range
0.25-0.58
Sector
Healthcare
Industry
Medical - Diagnostics & Research

Peer companies

  • Active Biotech AB (publ) (ACTI.ST)
  • Alligator Bioscience AB (publ) (ATORX.ST)
  • Scandinavian Real Heart AB (Publ) (HEART.ST)
  • Iconovo AB (publ) (ICO.ST)
  • Immunovia AB (publ) (IMMNOV.ST)
  • Luxbright AB (publ) (LXB.ST)
  • Pila Pharma AB (publ) (PILA.ST)
  • Spago Nanomedical AB (publ) (SPAGO.ST)

Open IDL Diagnostics AB (publ) (IDLDX.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.